Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice

被引:312
作者
Kim, Michael P. [2 ,3 ]
Evans, Douglas B. [2 ]
Wang, Huamin [4 ]
Abbruzzese, James L. [5 ]
Fleming, Jason B. [2 ]
Gallick, Gary E. [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA
[5] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA
关键词
NUDE-MOUSE MODEL; IN-VIVO; DRUG DEVELOPMENT; HUMAN-CELLS; IDENTIFICATION; VITRO; LINE;
D O I
10.1038/nprot.2009.171
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
For decades, xenografts using well-established human tumor cell lines have been the most commonly used models to study human cancers in mice. More recently, human tumors implanted directly into immunodeficient mice have become increasingly popular as evidence accrues that they more accurately recapitulate features of patient tumors. Here we describe our protocols for the orthotopic and heterotopic implantation of pancreatic cancer cell lines and freshly isolated patient tumors into immunodeficient mice. We also describe procedures for the digestion of tumors into single-cell suspensions for the isolation of subpopulations of tumor cells. Orthotopic or heterotopic implantation of established cell lines requires 1-2 h, with 1-cm tumors arising after 2-5 weeks. Engraftment of patient tumor samples takes similar to 2 h and growth of palpable tumor requires similar to 14 weeks. Once established, direct xenograft tumors require 2 and 5 h for heterotopic and orthotopic implantation, respectively, and 5-6 weeks for palpable tumor growth.
引用
收藏
页码:1670 / 1680
页数:11
相关论文
共 31 条
[11]   Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: A bridge to the clinic [J].
Hoffman, RM .
INVESTIGATIONAL NEW DRUGS, 1999, 17 (04) :343-359
[12]   The pediatric preclinical testing program: Description of models and early testing results [J].
Houghton, Peter J. ;
Morton, Christopher L. ;
Tucker, Chandra ;
Payne, Debbie ;
Favours, Edward ;
Cole, Claire ;
Gorlick, Richard ;
Kolb, E. Anders ;
Zhang, Wendong ;
Lock, Richard ;
Carol, Hernan ;
Tajbakhsh, Mimi ;
Reynolds, C. Patrick ;
Maris, John M. ;
Courtright, Joshua ;
Keir, Stephen T. ;
Friedman, Henry S. ;
Stopford, Charles ;
Zeidner, Joseph ;
Wu, Jianrong ;
Liu, Tiebin ;
Billups, Catherine A. ;
Khan, Javed ;
Ansher, Sherry ;
Zhang, Jian ;
Smith, Malcolm A. .
PEDIATRIC BLOOD & CANCER, 2007, 49 (07) :928-940
[13]   NOD/SCID/γcnull mouse:: an excellent recipient mouse model for engraftment of human cells [J].
Ito, M ;
Hiramatsu, H ;
Kobayashi, K ;
Suzue, K ;
Kawahata, M ;
Hioki, K ;
Ueyama, Y ;
Koyanagi, Y ;
Sugamura, K ;
Tsuji, K ;
Heike, T ;
Nakahata, T .
BLOOD, 2002, 100 (09) :3175-3182
[14]   Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials [J].
Johnson, JI ;
Decker, S ;
Zaharevitz, D ;
Rubinstein, LV ;
Venditti, J ;
Schepartz, S ;
Kalyandrug, S ;
Christian, M ;
Arbuck, S ;
Hollingshead, M ;
Sausville, EA .
BRITISH JOURNAL OF CANCER, 2001, 84 (10) :1424-1431
[15]   Core signaling pathways in human pancreatic cancers revealed by global genomic analyses [J].
Jones, Sian ;
Zhang, Xiaosong ;
Parsons, D. Williams ;
Lin, Jimmy Cheng-Ho ;
Leary, Rebecca J. ;
Angenendt, Philipp ;
Mankoo, Parminder ;
Carter, Hannah ;
Kamiyama, Hirohiko ;
Jimeno, Antonio ;
Hong, Seung-Mo ;
Fu, Baojin ;
Lin, Ming-Tseh ;
Calhoun, Eric S. ;
Kamiyama, Mihoko ;
Walter, Kimberly ;
Nikolskaya, Tatiana ;
Nikolsky, Yuri ;
Hartigan, James ;
Smith, Douglas R. ;
Hidalgo, Manuel ;
Leach, Steven D. ;
Klein, Alison P. ;
Jaffee, Elizabeth M. ;
Goggins, Michael ;
Maitra, Anirban ;
Iacobuzio-Donahue, Christine ;
Eshleman, James R. ;
Kern, Scott E. ;
Hruban, Ralph H. ;
Karchin, Rachel ;
Papadopoulos, Nickolas ;
Parmigiani, Giovanni ;
Vogelstein, Bert ;
Velculescu, Victor E. ;
Kinzler, Kenneth W. .
SCIENCE, 2008, 321 (5897) :1801-1806
[16]   Nuclear factor-κB maintains TRAIL resistance in human pancreatic cancer cells [J].
Khanbolooki, Sanaz ;
Nawrocki, Steffan T. ;
Arumugam, Thiruvengadam ;
Andtbacka, Robert ;
Pino, Maria S. ;
Kurzrock, Razelle ;
Logsdon, Craig D. ;
Abbruzzese, James L. ;
McConkey, David J. .
MOLECULAR CANCER THERAPEUTICS, 2006, 5 (09) :2251-2260
[17]  
KIM MP, 2009, P 2009 AM SOC CLIN O, P142
[18]   Identification of pancreatic cancer stem cells [J].
Li, Chenwei ;
Heidt, David G. ;
Dalerba, Piero ;
Burant, Charles F. ;
Zhang, Lanjing ;
Adsay, Volkan ;
Wicha, Max ;
Clarke, Michael F. ;
Simeone, Diane M. .
CANCER RESEARCH, 2007, 67 (03) :1030-1037
[19]   Orthotopic transplantation models of pancreatic adenocarcinoma derived from cell lines and primary tumors and displaying varying metastatic activity [J].
Loukopoulos, P ;
Kanetaka, K ;
Takamura, M ;
Shibata, T ;
Sakamoto, M ;
Hirohashi, S .
PANCREAS, 2004, 29 (03) :193-203
[20]  
Nawrocki ST, 2004, MOL CANCER THER, V3, P59